We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

32 hedge funds and large institutions have $6.03M invested in AYTU BioPharma in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more capital invested

Capital invested by funds: $5.39M → $6.03M (+$638K)

0.16% more ownership

Funds ownership: 0.68% → 0.84% (+0.16%)

14% less funds holding

Funds holding: 37 → 32 (-5)

33% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 12

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Holders
32
Holders Change
-5
Holders Change %
-13.51%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
8
Reduced
12
Closed
9
Calls
$177K
Puts
–
Net Calls
+$177K
Net Calls Change
-$44K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$2.96M
2
Renaissance Technologies
Renaissance Technologies
New York
+$125K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$31.5K
4
Goldman Sachs
Goldman Sachs
New York
+$11.5K
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$7.78K

Top Sellers

Rank Fund Capital Flow
1
PSC
Piper Sandler & Co
Minnesota
-$297K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$275K
3
Morgan Stanley
Morgan Stanley
New York
-$173K
4
Citadel Advisors
Citadel Advisors
Florida
-$122K
5
OQS
Occudo Quantitative Strategies
Florida
-$83K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$2.57M +$2.96M +118,997 New
Renaissance Technologies
2
Renaissance Technologies
New York
$827K +$125K +5,020 +15%
Vanguard Group
3
Vanguard Group
Pennsylvania
$780K -$275K -11,054 -23%
BlackRock
4
BlackRock
New York
$589K -$3.51K -141 -0.5%
Millennium Management
5
Millennium Management
New York
$287K -$37.1K -1,493 -10%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$279K +$1.99K +80 +0.6%
Commonwealth Equity Services
7
Commonwealth Equity Services
Massachusetts
$118K +$2.49K +100 +2%
State Street
8
State Street
Massachusetts
$105K – – –
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$62K +$31.5K +1,268 +79%
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$61K -$66.3K -2,666 -49%
SFI
11
Susquehanna Fundamental Investments
Pennsylvania
$58K -$22.5K -904 -25%
Morgan Stanley
12
Morgan Stanley
New York
$56K -$173K -6,946 -73%
Goldman Sachs
13
Goldman Sachs
New York
$54K +$11.5K +464 +23%
Northern Trust
14
Northern Trust
Illinois
$53K -$249 -10 -0.4%
TRCT
15
Tower Research Capital (TRC)
New York
$30K -$2.11K -85 -6%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$26K +$7.78K +313 +36%
SSA
17
Schonfeld Strategic Advisors
New York
$18K -$124 -5 -0.6%
HAIM
18
Hunter Associates Investment Management
Pennsylvania
$12K – – –
Bank of New York Mellon
19
Bank of New York Mellon
New York
$11K – – –
Group One Trading
20
Group One Trading
Illinois
$9K +$6.34K +255 +150%
IA
21
IFP Advisors
Florida
$8K – – –
Osaic Holdings
22
Osaic Holdings
Arizona
$6K -$522 -21 -6%
Federated Hermes
23
Federated Hermes
Pennsylvania
$6K +$3.03K +122 +76%
Wells Fargo
24
Wells Fargo
California
$3K -$75 -3 -2%
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
$1K -$25 -1 -4%
1
2

AYTU Hedge Fund Activity: Q1 2022 in Review

32 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q1 2022, worth a combined $6.03M — up 12% from $5.39M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of AYTU and 4 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 8 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $2.96M. The largest seller was Piper Sandler & Co, exiting entirely with an estimated $297K sold.

  • 32 institutional investors held AYTU BioPharma (AYTU) as of Q1 2022, down from 37 in Q4 2021.
  • Funds reported $6.03M of AYTU BioPharma stock for Q1 2022, up 12% quarter-over-quarter.
  • 4 funds opened new AYTU BioPharma positions in Q1 2022 and 9 closed out, a net change of -5 holders.
  • The largest AYTU BioPharma buyer in Q1 2022 was Armistice Capital, an estimated $2.96M added.
  • The largest AYTU BioPharma seller in Q1 2022 was Piper Sandler & Co, an estimated $297K sold.

Based on aggregated 13F filings for Q1 2022.